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Abstract
Background: Lynch syndrome (LS) is an inherited, cancer predisposition syndrome associated with an increased
risk of colorectal, endometrial and other cancer types. Identifying individuals with LS allows access to cancer risk
management strategies proven to reduce cancer incidence and improve survival. However, LS is underdiagnosed
and genetic referral rates are poor. Improving LS referral is complex, and requires multisystem behaviour change.
Although barriers have been identified, evidence-based strategies to facilitate behaviour change are lacking. The
aim of this study is to compare the effectiveness of a theory-based implementation approach against a non-theory
based approach for improving detection of LS amongst Australian patients with colorectal cancer (CRC).
Methods: A two-arm parallel cluster randomised trial design will be used to compare two identical, structured
implementation approaches, distinguished only by the use of theory to identify barriers and design targeted
intervention strategies, to improve LS referral practices in eight large Australian hospital networks. Each hospital
network will be randomly allocated to a trial arm, with stratification by state. A trained healthcare professional will
lead the following phases at each site: (1) undertake baseline clinical practice audits, (2) form multidisciplinary
Implementation Teams, (3) identify target behaviours for practice change, (4) identify barriers to change, (5) generate
intervention strategies, (6) support staff to implement interventions and (7) evaluate the effectiveness of the intervention
using post-implementation clinical data. The theoretical and non-theoretical components of each trial arm will be
distinguished in phases 4–5. Study outcomes include a LS referral process map for each hospital network, with evaluation
of the proportion of patients with risk-appropriate completion of the LS referral pathway within 2months of CRC resection
pre and post implementation.
Discussion: This trial will determine the more effective approach for improving the detection of LS amongst patients with
CRC, whilst also advancing understanding of the impact of theory-based implementation approaches in complex health
systems and the feasibility of training healthcare professionals to use them. Insights gained will guide the development of
future interventions to improve LS identification on a larger scale and across different contexts, as well as efforts to address
the gap between evidence and practice in the rapidly evolving field of genomic research.
Trial registration: ANZCTR, ACTRN12618001072202. Registered on 27 June 2018.
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Background
Evidence translation for genetics and genomics
Advances in genetic and genomic research have prom-
ised to transform future approaches to disease preven-
tion, detection and treatment [1, 2]. In the clinical
setting, the development of high-throughput technolo-
gies for genetic sequencing and analysis has generated
new opportunities for improved diagnosis of genetic dis-
orders, personalised targeted treatments (particularly for
cancer patients), prenatal screening and diagnosis,
pharmacogenomics and population-based assessment of
disease risk [3, 4]. However, the process of integrating
these changes into existing healthcare systems has been
slow and challenging, with health systems struggling to
keep up with the exponential speed at which the genom-
ics evidence-base is evolving [4–6].
Next-generation sequencing platforms have improved
the affordability and feasibility of detecting rare, but
highly penetrant mutations in cancer predisposition
genes, such as TP53, BRCA1, BRCA2, APC and the mis-
match repair genes - MLH1, MSH2, MSH6 and PMS2
[2]. With increasing recognition of the clinical utility of
genetic information, the number of patients being
offered genetic testing is increasing, putting pressure on
specialist genetics services that have limited capacity to
cope with the increased demand [1, 6]. Some genetics-
related tasks have already been deployed to clinicians
(sometimes termed “mainstreaming”), for example with
surgeons or oncologists now ordering genetic tests and
interpreting pathology reports to determine risk and
whether to refer to genetics [6–10]. This requires in-
corporating new practices and behaviours; however, the
success of these has been mixed (e.g. with suboptimal
referral rates identified) [7, 11]. With more mainstream-
ing of genomics into health systems on the horizon,
there is a need to understand how best to incorporate
genetic responsibilities into clinical practice.
Frameworks and theory to support implementation
Implementation science uses evidence-based strategies
(e.g. system change interventions, quality monitoring
tools) to promote the behavioural change necessary for
effective implementation, and can be applied to all trans-
lational phases of the genomic research continuum to
promote uptake in the clinical setting [5, 12]. Implemen-
tation science frameworks (e.g. the consolidated frame-
work for implementation research (CFIR) [13]; reach,
effectiveness, adoption, implementation and mainten-
ance (RE-AIM) [14]; promoting action on research im-
plementation in health services framework (PAHRIS)
[15]) consolidate these strategies to provide guided, sys-
tematic approaches that can be used by researchers and/
or clinicians to enhance implementation. However, a re-
cent literature review demonstrated that less than 2% of
studies aimed at translating genetics and genomics re-
search into clinical practice explicitly made use of these
implementation science frameworks [5]. Given the pace
at which genomic research is expanding, failure to utilise
evidence-based implementation frameworks is likely to
widen the gap between evidence and practice [5].
Implementation frameworks with a theoretical basis
can enhance understanding of the factors influencing
implementation success or failure and have been proven
effective in producing health system behaviour change
across a number of settings [16–18]. One example is the
theoretical domains framework (TDF), which synthesises
a range of behaviour change theories to aid the identifi-
cation of behaviour change barriers, which can then be
specifically targeted by evidence-based interventions
[19]. The TDF has been used extensively in clinical prac-
tice to promote healthcare professional behaviour
change, but with variable success [16, 20–22]. Under-
standing factors that mediate intervention success across
complex and unpredictable health systems remains a
challenge [23, 24]. The success or failure of an interven-
tion is likely to result from a complex interplay between
a number of factors, including the nature of the clinical
problem; novelty of proposed changes; appropriateness
of the chosen implementation framework; attributes of
the individual(s) driving the change (e.g. level of experi-
ence, psychosocial determinants) and contextual influ-
ences at local, organisational and system levels [25]. In
such settings, rigorous trials of different implementation
approaches may help to begin unravelling these
complexities.
Implementing Lynch syndrome evidence into practice
Lynch syndrome (LS) is one of the genetic syndromes
that has been impacted by these implementation chal-
lenges. LS is an autosomal dominant cancer predispos-
ition syndrome conferring an increased risk of
colorectal, endometrial and other cancer types [26].
Identifying individuals affected by LS allows access to
cancer risk management strategies (e.g. colonoscopic
surveillance, risk-reducing hysterectomy) proven to re-
duce cancer incidence and improve survival [27, 28].
Despite guidelines recommending universal LS screening
strategies for patients with LS-associated cancers, the
condition remains largely underdiagnosed and current
genetic referral rates are suboptimal [11]. In Australia,
little is known about LS diagnostic pathways or the prac-
tices hindering rates of referral - partially owing to the
challenges of linking data between hospitals, pathology
providers and familial cancer clinics [29], as well as a
lack of standardised referral pathways upon which these
data can be mapped to identify system failures. Whilst
Brennan and colleagues identified various stages at
which cases of colorectal cancer (CRC) slipped through
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the LS referral cracks in hospitals in the Australian Cap-
ital Territory [11], further work is needed to establish
practices at a national level.
Recently, a pilot study [30] was conducted at two large
Australian hospitals to improve the identification of LS
amongst patients with CRC using the theoretical domains
framework implementation (TDFI) approach: a theory-
grounded, 6-step approach that combines the TDF with
implementation science principles to systematically pro-
mote behaviour change in accordance with clinical guide-
lines [16]. The following TDFI steps were carried out at
each site: (1) local multidisciplinary teams formed to map
current LS referral processes; (2) target behaviours were
identified using discussion supported by a retrospective
audit; (3) barriers to those behaviours were identified
using the validated Influences on Patient Safety Behav-
iours Questionnaire (IPSBQ) and TDFI-guided focus
groups; (4) interventions were co-designed to address bar-
riers using focus groups; (5) interventions were co-
implemented and (6) impact of the intervention was eval-
uated [30]. The rationale for this approach was to actively
involve healthcare professionals throughout the imple-
mentation process, particularly by using their tacit know-
ledge to contextualise problems and co-design pragmatic
interventions [31] alongside input from implementation
experts with theoretical expertise in behaviour change
[32].
The pilot study yielded mixed results, with changes in
some behaviours (e.g. improved ordering of supplemen-
tary pathology tests, standardised wording of pathology
reports) but no overall improvement in the primary
study outcome (number of LS referrals) [30]. Post-
implementation interviews were conducted with health-
care professionals involved in the LS implementation
pilot study, with thematic analysis highlighting key im-
plementation challenges across both theoretical and
practical boundaries. These included (1) the accessibility
of theory to healthcare professionals (e.g. lack of under-
standing and/or perceived necessity of behaviour change
theory), (2) compliance with theory by healthcare profes-
sionals (e.g. a tendency to jump straight into solution
generation rather than following TDFI steps), (3) navi-
gating the system (e.g. lengthy governance processes,
lack of external researcher knowledge about internal
stakeholder networks and contacts) and (4) stakeholder
management (e.g. lack of researcher awareness about
existing internal politics and hierarchies).
Refining implementation approaches and testing the
impact of theory
One approach to solving both the theory-related and
practical problems presented is to train healthcare
professionals from within the system to use an imple-
mentation science framework as part of a research
study, specifically the TDFI approach in this instance.
Training healthcare professionals from within the sys-
tem is likely to alleviate (1) theoretical barriers (ac-
cessibility and compliance) via education about the
rationale and demonstrated benefits of a theory-based
approach, and upskilling to ensure the approach is
applied accurately and (2) practical barriers (navigat-
ing the system and stakeholder management) by
drawing on knowledge from within the system about
existing processes, bureaucracy and internal stake-
holder networks and politics. Not only is this likely to
enhance the feasibility of the TDFI approach for im-
proving clinical practice in genomics, it is also likely
to improve the fidelity of delivery of the approach,
and the rigour under which it is tested - crucial chal-
lenges that need to be addressed to advance the field
of implementation science [32].
Theoretically underpinned implementation frameworks
can optimise and contextualise the design of behaviour
change interventions, whilst increasing opportunities to
understand generalizability to other settings [33]. However,
to understand the impact of the use of theory in an imple-
mentation approach, and to advance the science of behav-
iour change in healthcare, it is important to distinguish the
theoretical components (e.g. use of the TDF to identify bar-
riers and generate targeted intervention strategies), holding
as many of the other aspects of the implementation ap-
proach constant. Therefore, this study will compare the ef-
fectiveness of two identical, structured implementation
approaches delivered by trained healthcare professionals,
distinguished only by the use of theory to identify barriers
and to design targeted interventions, in improving clinical
practice for identifying patients with LS.
Methods
Design
This protocol is reported in line with the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) checklist (Additional file 1) [34]. The re-
sults will be reported in line with the Consolidated Stan-
dards of Reporting Trials statement extension for social
and psychological interventions (CONSORT-SPI 2018
extension) [35]. Consequently, the CONSORT-SPI flow
diagram is reported in this protocol (see Fig. 1).
A parallel, cluster randomised trial will be used to
test for differences between a theory-based implementa-
tion approach (TDFI) and a non-theory based imple-
mentation approach to improving LS referral practices
in eight large Australian hospital networks across three
states [New South Wales (n=4), Victoria (n=2), and
Western Australia (n=2)]. As sharing of staff and re-
sources in networked hospitals is likely to lead to corre-
lations between outcomes, each hospital network will
comprise a separate cluster in this trial (i.e. eight
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clusters in total). Hospital networks will be randomly
allocated to the theory arm or non-theory arm using a
computer-generated random sequence. To account for
differences in region-specific LS detection pathways, the
randomisation will be stratified by participating states,
with the same number of networks from each state al-
located to theory and non-theory arms (a 1:1 allocation
ratio). A theory-based, mixed methods process evalu-
ation will be conducted alongside the trial to investigate
intervention fidelity, potential mechanisms of impact,
Fig. 1 Consolidated Standards of Reporting Trials statement extension for social and psychological interventions (CONSORT-SPI) flow diagram.
Diagram of participant (hospital networks) recruitment. *Numbers to be incorporated as trial progresses
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mediators and contextual moderators, for both ap-
proaches [24, 36].
Overview of implementation intervention
At each hospital network, a locally employed healthcare
professional (see “Implementation Lead recruitment”)
from within the system will be trained to lead a 7-phase
implementation intervention approach (see “Procedure”).
Outcomes
Pre-implementation outcomes
CRC surgery, pathology, and familial cancer clinic (FCC)
clinical data will be retrospectively collected across all
hospital networks for patients admitted during a 24-
month period prior to study commencement, to demon-
strate LS referral pathway clinical practice. The data will
be cross-referenced with LS referral maps to be con-
structed for each hospital network. The proportion of
patients who transition to each step, in adherence to the
pathway map will be calculated, leading to the identifica-
tion of bottlenecks. The referral maps and bottlenecks
will be compared across hospital networks, with particu-
lar attention to potential differences in processes be-
tween geographical regions. A validated TDF-based
questionnaire (Influences on Patient Safety Behaviours
Questionnaire) [37] will be used to quantitatively evalu-
ate psychosocial barriers to risk-appropriate completion
of the LS referral pathway. Qualitative focus group data
will be used to understand key barriers in context.
Post-implementation outcomes
The primary post-implementation quantitative outcome
will be the change in the proportion of patients with
risk-appropriate completion of the site-specific LS
tumour testing and referral pathway within 2 months of
CRC resection. Secondary outcomes will be (1) propor-
tion of high risk-patients who were referred to the FCCs
(sensitivity of referral), (2) proportion of referred pa-
tients who attended FCC and (3) proportion of patients
with missing testing and referral data.
Recruitment
Study site recruitment
The research team approached ten Australian hospital
networks to participate. Due to the difficulty of obtain-
ing the number of CRC resections performed by hospital
per year, the eligibility criteria used to identify networks
was defined as “hospitals where CRC resections are rou-
tinely performed”. A hospital network may consist of a
single hospital or several hospitals (including co-located
or off-site pathology laboratories and FCCs) in which
staff and resources are shared. In each cluster, at least
one hospital of > 500 beds is included. The Chief Investi-
gator steering committee (see Additional file 2 for study
personnel roles and responsibilities) was consulted to
identify hospitals to approach to participate. Of the ten
hospital networks approached, two were excluded.
Research governance applications for eight networks (each
consisting of 1–3 individual hospital sites) are being pre-
pared for or reviewed by hospital research governance of-
fices, and formal enrolment will be concluded when
research governance approval is granted for each hospital
network. No exact numbers of patients with colorectal
cancer who undergo resection were available for the indi-
vidual hospitals; rough estimates are 100–250 per hospital
network per annum.
Implementation Lead recruitment
At each hospital network, a locally employed healthcare
professional will be appointed as a paid Implementation
Lead for one day per week over a 24-month period to
coordinate the implementation approach and to oversee
data collection. They will have a professional under-
standing of the LS patient pathway, and the ability to
motivate other LS stakeholders to engage with imple-
mentation processes. These criteria will be used to select
the most appropriate candidate for the Implementation
Lead role at each hospital network.
LS patient pathway stakeholder recruitment
Using snowball recruitment methods, stakeholders in
the LS patient referral pathway (e.g. surgeons, patholo-
gists, oncologists, registrars, genetic counsellors) will be
invited by the Implementation Lead to participate in one
or more study activities relevant to their role at time-
points throughout the implementation approach. These
include process map meetings, questionnaires, focus
groups and intervention implementation planning
meetings.
Allocation and concealment
Block randomisation for this study was carried out at
the level of the hospital networks. Each hospital network
(and associated pathology laboratory and FCC) was allo-
cated to the theory arm or non-theory arm by a member
of the research team not involved in recruitment of hos-
pital networks, using a random computer-generated
sequence, with stratification by state. The research team
will be aware of the trial arm allocation to train the Im-
plementation Leads; however, the allocation will be con-
cealed from the Implementation Leads, and the
individual participants they recruit [Implementation
Team members (see Phase 2) and LS patient pathway
stakeholders]. Following randomised allocation, Imple-
mentation Leads were trained in one of two structured
implementation approaches: either a theory-based ap-
proach or a non-theory based approach. Allocation has
been concealed from the Chief Investigators. To prevent
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selection bias, all hospital networks were recruited prior
to randomisation, and all adult patients undergoing a
CRC resection at each hospital network within the study
timeframe will be included in the study. Currently, there
are no anticipated circumstances when unblinding
would be considered permissible. Given the inability to
fully control interactions between individuals at different
networks involved in the trial, we accept that masking of
Implementation Leads and individual participants may
be compromised. Plans to investigate the success of
masking amongst Implementation Leads are being incor-
porated into the process evaluation.
Measures
Clinical data collection
Patient-level clinical practice data relating to the CRC and
LS referral pathway will be extracted from relevant surgi-
cal, pathology, and FCC databases by the Implementation
Leads (see Additional file 2 for variables). Patient data will
be collected throughout the implementation of the inter-
vention, and outcome data will be collected for up to 9
months after the end of the intervention strategies. Pa-
tients will be eligible for inclusion if they undergo CRC re-
section at participating hospital networks within the time
periods for data collection and are aged over 18 years at
the time of resection. Given the short duration of the trial
and minimal risk of harm, a formal data monitoring com-
mittee will not be required. An ethics-committee-
approved data management plan has been presented to re-
search governance officers and will be refined for each




The validated IPSBQ [37] will be used to assess barriers
to the relevant target behaviour for change in relation to
LS identification and referral, incorporating additional
items to reflect the 14-domain TDF developed by Cane
et al. (2012) [19]. Participants in the theory-based imple-
mentation arm will be provided with results from the
IPSBQ to facilitate barrier identification and develop-
ment of targeted intervention strategies as part of the
implementation process. Participants in the non-theory
trial arm will also complete the IPSBQ, but only for the
purpose of measuring changes in perceived barriers pre-
post intervention.
Theory-based focus group schedule
The content of the theory-based focus group schedules
and additional materials (see Additional file 2) was
developed based on the TDFI to encourage discussion of
barriers explicitly in the context of the TDF [16, 38].
Non-theory based focus group schedule
The content of the non-theory based focus groups and
additional materials (see Additional file 2) was developed
to promote generic discussion of barriers based on intu-
ition and tacit knowledge, and does not include IPSBQ
results or TDF-guided questions about barriers and in-
terventions [38].
Procedure (detailed description of implementation
intervention)
The Implementation Lead at each site will oversee the 7
study phases described below. Phases 4 and 5 will differ-
entiate the theory-based and non-theory based compo-
nents of the implementation approaches, according to
trial arm allocation; the non-theory based components
have been modified from the TDFI approach [16].
Phases 1–3 and 6–7 will remain the same for both arms.
The study procedures for enrolment, intervention proce-
dures and assessment are presented in the SPIRIT
diagram in Fig. 2.
Implementation Lead training and ongoing support
The standard training content received by both groups
was developed based on common components of com-
prehensive implementation initiatives utilised by health
services for the purposes of improvement [16, 39]. Dif-
ferences in training materials used in the trial arms will
be distinguished only by the inclusion of additional
TDF-guided content in the theory-based implementation
arm. The training will comprise an introduction to im-
plementation science and specific instructions, practical
activities and tools for moving through the 7 phases of
the implementation approaches described below (see
Additional file 2 for description of training contents).
Implementation Leads will be informed of planned tele-
conference calls with the research team over the study
period to support the delivery of each phase, and pro-
vided with additional tools for recording study-related
activities for process evaluation purposes. These telecon-
ferences will be used to identify and address challenges
to participant recruitment and to record and manage
any unintended effects of the interventions. Site-specific
data management plans, including measures to protect
confidentiality of individual participants, will be commu-
nicated to Implementation Leads during teleconferences.
Phase 1 - undertake baseline audit
The Implementation Leads at each site will undertake
data extraction using the clinical practice data extraction
tool to establish baseline evidence on existing LS referral
practices (see Additional file 2 for data variables). These
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data will be de-identified and securely transported to the
research team. The research team will carry out data
checks and undertake site specific analyses for the pur-
pose of presenting local results back to each site.
Phase 2 - form the Implementation Team
At each site, key LS patient pathway stakeholders
will be identified by the Implementation Lead and
invited to form an Implementation Team of 8–10
multidisciplinary change agents [16, 21, 40]. This will
consist of healthcare professionals and administrators
working in departments involved in the LS identifi-
cation and referral pathway (including, but not lim-
ited to genetic counsellors, colorectal surgeons,
pathologists, oncologists, nurses, administrative staff,
multidisciplinary team (MDT) meeting coordinators).
These individuals will bring expertise from various
roles and departments, and therefore increase the
likelihood of implementation success [41]. The Im-
plementation Team (led by the Implementation Lead
and with support from the research team) will work
together through each phase and will also assist in
recruiting other LS patient pathway stakeholders to
relevant study activities.
Phase 3 - identify target behaviours for change
At each site, the Implementation Lead and Implementa-
tion Team will participate in two meetings to identify
site-specific target behaviours for change. Meeting one
will involve a discussion of LS referral pathways, where
participants will discuss what they believe current pro-
cesses and practice to be. Based on these discussions,
the Implementation Lead will generate a LS referral
pathway process map, which will be later refined in col-
laboration with the research team. These site-specific
process maps will allow the research team to identify
key aspects of the process to improve and any key hos-
pital differences.
Prior to meeting two, baseline clinical data (ex-
tracted in phase 1 and analysed by the research team)
will be mapped to relevant components of the referral
process. During the meeting, Implementation Team
members will reflect on their experiences of and be-
liefs about the referral process in light of the baseline
clinical data, and explore possible system and/or be-
havioural change targets. Identifying the target for be-
haviour change will involve consideration of the
impact of changing the behaviour on the desired out-
come; whether the behaviour change is achievable;
Fig. 2 Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) diagram. Schedule for enrolment, intervention procedures and
assessment. IPSBQ, Influences on Patient Safety Behaviours Questionnaire
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the likely impact (positive or negative) on other, re-
lated behaviours and the degree to which the behav-
iour can be measured [42]. The Implementation Lead
and research team will use this information to con-
firm the target behaviour(s) for change.
Phase 4 - identify and confirm barriers to change
LS patient pathway stakeholders in both arms will
complete the IPSBQ [37], and be invited to participate
in a focus group. Focus groups will be facilitated (by the
Implementation Lead) according to a theory-based or
non-theory based format, depending on trial arm alloca-
tion (see Additional file 2 for focus group schedules). A
member of the research team (NT) will attend meetings
via video link to support discussions and elicit more in-
depth responses.
Theory-based implementation arm Focus group par-
ticipants will be made aware that the IPSBQ assesses
barriers according to theoretical domains explicitly
linked to the identification of behaviours. They will be
presented with the IPSBQ results from their site, discuss
barriers in the context of the TDF and come to a con-
sensus about the top 3–4 barriers overall. The research
team will undertake a theory-based analysis of the focus
group data to generate an initial implementation pack-
age, based on identification of intervention strategies in-
formed by behaviour change techniques (BCTs) matched
to identified barriers. This package will be discussed and
refined by the Implementation Lead and the research
team.
Non-theory based implementation arm In contrast to
the theory-based arm, participants will have completed
the questionnaire for the purposes of measuring percep-
tions of barriers pre-post intervention, but will not be
shown the results. Focus group participants will be asked
to consider the confirmed target behaviour and develop
intervention strategies based on intuition and tacit
knowledge. Members of the research team (without ex-
pertise in coding and operationalising the TDF and BCTs
but with expertise in implementation) will undertake a
non-theory based analysis of the focus group data to
generate an initial implementation package, based on
identification of intuitive intervention strategies to ad-
dress intuitively identified barriers. This package will be
discussed and refined by the Implementation Lead and
the research team.
Phase 5 - generate intervention strategies
For both arms, the Implementation Lead will invite LS pa-
tient pathway stakeholders to participate in a second focus
group to identify and confirm intervention strategies. As in
phase 4, focus groups will be facilitated differently
according to trial arm allocation (see Additional file 2 for
focus group schedules). Detailed descriptions of the inter-
vention strategies used to address key barriers will be re-
ported in accordance with Standards for Reporting
Implementation Studies (StaRI) guidelines [43].
Theory-based implementation arm Focus group par-
ticipants will be presented with a table of barriers
mapped to the TDF and solutions mapped to BCTs.
Non-theory based implementation arm In the non-
theory based arm, participants will be presented with a
table of intuitively derived barriers and intuitively de-
rived solutions.
Participants will be provided with a feasibility/impact
matrix for each proposed strategy in both arms, and
asked their opinions on the anticipated effort needed,
feasibility and impact, guided by the APEASE criteria
[38]. From this, the core intervention components will
be refined.
Phase 6 - support staff to implement interventions
Intervention strategies generated in phase 5 will be imple-
mented using general implementation science principles
(i.e. the need for management support and commitment
among target group members, use of boundary spanners,
flexibility driven by local context, incorporation into estab-
lished structures) [16]. With a template provided by the re-
search team, Implementation Leads will create a report that
will outline findings from phase 1–5, the intervention pack-
age and a plan for implementation. This will be submitted
to senior management from departments affected by any
proposed intervention strategies (e.g. CRC surgery, path-
ology and FCCs), and may require revision based on man-
agement feedback. Once management approves the
proposed implementation plan, intervention strategies will
then be presented to relevant forums (e.g. MDT meetings,
pathology team meetings) to gain feedback that will allow
the development of a broader structure to disseminate find-
ings. The Implementation Lead will then work collabora-
tively with the Implementation Team to implement the
intervention package over a 6-month period.
Phase 7 - evaluate intervention and assess practice and
culture change
Following the 6-month intervention implementation
period, LS patient pathway stakeholders from both arms
will be invited to complete a second IPSBQ to assess any
changes in perceived barriers to improving LS referral
and diagnosis, as part of the simultaneous process evalu-
ation. In addition, post-intervention clinical data will be
extracted and compared to baseline clinical data to as-
sess the impact of the intervention on clinical practice
change, via assessment of the proportion of patients with
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CRC with risk-appropriate completion of the LS referral
pathway.
Analysis plan
Sample size and statistical power
The qualitative and descriptive outcomes (including the
LS referral process maps, the descriptive baseline clinical
data, the IPSBQ questionnaire results) are not amenable
to sample size calculations. While it would be ideal to
carry out a power calculation for the proportion of pa-
tients with risk-appropriate completion of the LS referral
pathway, it is not possible in this situation due to the
lack of exploratory trials in this area, including paucity
of information on baseline outcomes, the number of pa-
tients per hospital and the intra-cluster coefficient (ICC)
for outcomes in this trial. The power calculation will
therefore be carried out once the baseline information is
obtained. We also acknowledge that despite random al-
location of the eight clusters, the characteristics may not
be balanced between the two arms of the trial, represent-
ing a limitation of this trial.
Analysis of baseline clinical data
For each hospital network, the baseline clinical data ex-
tracted in phase 1 will be analysed for concordance with
the hospital-specific LS referral pathway. Patients who
transition through each step - in adherence to the path-
way map - will be leading to the identification of bottle-
necks. In the event that 100% adherence is
demonstrated at baseline, investigators from the relevant
site will be offered the option of continuing or with-
drawing from the trial.
Assessing perceived barriers via questionnaire
Results from the IPSBQ will be analysed using descrip-
tive statistics. Inter-item correlation will be tested to as-
sess the internal consistency of each IPSBQ subscale
(optimal range = 0.15–0.50). Pre-post questionnaire re-
sults from both trial arms will be used to assess changes
in barriers as part of the aforementioned process
evaluation.
Theory-based focus group data analysis to design
intervention strategies
Stage 1: in line with previous approaches [16], focus
group data will be thematically analysed using a deduct-
ive approach, with coding according to the TDF do-
mains. The key barrier domains emerging from the
focus groups will be cross referenced with those identi-
fied by the IPSBQ, and discrepancies noted.
Stage 2: analysis of the top 3–4 barrier domains will
identify overlap with existing theories of behaviour
change. These theories will be reviewed to identify ex-
perimental data that has demonstrated the mechanistic
effect of specific behaviour change strategies for eliciting
behaviour change. This review will be used to identify
categories of BCTs that may be effective [44, 45]. These
techniques will be operationalised into context-specific
intervention strategies to address the key barriers to
generate an initial intervention package, which will be
reviewed and refined in collaboration with each Imple-
mentation Lead.
Non-theorybased focus group data analysis to design
intervention strategies
Stage 1: inductive analysis will be applied to identify key
intuitively derived barriers reported in the focus groups.
Stage 2: context-specific intervention strategies will be
identified to address the key barriers to generate an
initial intervention package, which will be reviewed and
refined in collaboration with each Implementation Lead.
Focus group data analysis to refine the intervention
package
Deductive analysis on the second set of focus group data
will be applied in both trial arms, based on the APEASE
[38] criteria, to assess the perceptions of the feasibility
and impact of each proposed intervention strategy. From
this, the core intervention components will be refined.
Assessing clinical practice change
The analysis of each dichotomous study outcome will be
conducted at the individual patient level, using general-
ised estimating equation (GEE) adjustment for the clus-
tering of patients within hospital networks. We will
estimate the adjusted relative proportion (RR) of patients
with the outcome using a generalised linear regression
model with Poisson distribution, log link and robust
standard errors. The exposure variable will be the imple-
mentation intervention status of the respective hospital
network at the time of the patient’s CRC resection (pre
or post implementation-intervention). We will carry out
a two-sided test for each outcome, with the significance
threshold defined using the Bonferroni correction for
the number of outcomes tested. Missing testing and/or
referral data will be treated as tests not carried out, or
referral not completed, respectively. As covariates, we
will consider time period (3-month intervals), time since
implementation of intervention strategies (3-month in-
tervals), patient age at operation, sex and cancer stage.
The Quasi-Akaike information criterion will be used to
select which covariates to include in the final model. To
account for non-independence of within-hospital
outcomes, all GEE analyses will be carried out with ex-
changeable working correlation structures. We will carry
out sensitivity leave-one-out analyses by individually ex-
cluding hospital networks that accounted for more than
20% of the total patient numbers. If private patient
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status can be reliably obtained in at least six of eight trial
sites, a supplementary analysis will be performed using
private patient status as an additional covariate.
We note previous studies have found that a small
number of clusters can lead to inflated type I error rates,
and so-called small-sample corrections have been pro-
posed to address this. However, these small-sample cor-
rections were found to be too conservative for eight
clusters [46]. Consequently, we will carry out a supple-
mentary analysis using small-sample correction only for
those outcomes that are robustly significantly associated
with the implementation intervention status.
Trial status
This study commenced in July 2017. Hospital networks
have been approached to participate, have been rando-
mised and are engaged in the governance process. For-
mal recruitment of hospital networks will be complete
when research governance applications are approved.
Recruitment of individual participants for the research
activities described in phases 1–7 has not commenced,
and data collection has not commenced.
Discussion
The implementation of a systematic approach to LS
identification and referral is complicated, and requires
behavioural change amongst a multidisciplinary team of
healthcare professionals working within a complex and
unpredictable system. Results from the pilot study
highlighted a number of theoretical and practical issues
related to using a theory-based implementation ap-
proach to addressing the LS referral problem in this
context - a possible explanation for the lack of improve-
ment in referral overall [30]. By engaging someone from
within the system to lead the implementation approach
we seek to overcome these issues, enabling us to deter-
mine the extent to which the use of theory-based imple-
mentation approaches are (1) feasible in this setting and
(2) more effective than approaches reliant on the intu-
ition and tacit knowledge of healthcare professionals.
In addition to addressing a known clinical problem,
this will be the first study to compare the effects of two
implementation approaches, distinguished only by the
use of theory to determine psychosocial barriers and
intervention development to translate evidence into
practice in complex healthcare systems. By analysing
clinical practice data pre-post intervention, we will de-
termine the more effective approach for increasing the
proportion of patients with CRC with risk-appropriate
completion of the LS referral and testing pathway, and
the difference in the types of strategies generated
through theory-driven and intuitive approaches taken to
achieve this. This will also build on the work of Brennan
and colleagues [11] to enhance understanding of LS re-
ferral and diagnostic practices in Australia.
Limitations of this study include an inability to control
for differences between sites at individual, system and
organisational levels, reflecting the real-world challenges of
implementing practice-change interventions across diverse
and unpredictable healthcare systems. These challenges
emphasise the crucial need to study implementation trials
to understand what works, in what contexts, why and at
what costs [33]. The process evaluation, by providing valu-
able information for both approaches about intervention
fidelity, potential mechanisms of impact, mediators and
contextual moderators, will enable generalisability [24].
Time, resource and cost data will also be collected and in-
corporated into a microsimulation model (Policy1; cur-
rently validated for cervical [47] and bowel cancer [48] and
undergoing development for LS1), as part of an economic
evaluation to determine the most cost-effective approach.
Results from this study will not only guide the devel-
opment of future interventions to improve LS identifica-
tion on a larger scale and across different contexts, but
also interventions to translate evidence-based practice
changes from the rapidly evolving field of genomic
research into complex, dynamic healthcare systems.
Results will be shared within participating healthcare
systems, and to the wider community. We will also con-
tribute to the evolving Behaviour Change Technique
Taxonomy [49], and to the behavioural change and im-
plementation science community in advancing under-
standing on how to promote the effective use of
implementation strategies to enhance uptake of
evidence-based research.
Endnotes
1Policy1-Lynch comprises five model components, in-
cluding a model of natural history of CRC in LS, model
of screening for LS in incident CRC cases (i.e. identifying
probands), model of screening for LS in family members
(i.e. predictive genetic testing), model of prophylaxis and
surveillance (prophylactic surgery, colonoscopic surveil-
lance) and model of invasive cancer (cancer treatment
and survival).
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